Nasdaq
$3.19▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $985.6MShares out 3.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
12- 9.29Overnight26.09.29 09:264Ownership#●●●
MANNKIND CORP
MannKind Corp insider Steven B. Binder filed a Form 4 report regarding changes in beneficial ownership of securities as of September 25, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$3.19+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.25After-hours26.09.26 05:17144Ownership
MANNKIND CORP
MannKind Corp insider Steven B. Binder has filed an SEC Form 144 to report a proposed sale of company shares. This filing serves as a formal notification of the executive's plan to dispose of their holdings.…more
$3.19+0.00%vs prev closeView filingShare - 9.15Overnight26.09.15 09:004Ownership
MANNKIND CORP
Director Steven B. Binder of MannKind Corp reported a change in beneficial ownership of securities as of September 10, 2026. This filing is a Form 4 statement detailing the insider's transaction.…more
$3.19+0.00%vs prev closeView filingShare
11 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14After-hours26.10.15 05:01#●●●#●●●
MannKind to Participate in the Chardan Healthcare Conference
MannKind announced that its CEO will participate in a panel discussion on chronic respiratory disease innovation at the Chardan Healthcare Conference. Management will also engage in one-on-one meetings with investors during the event.…more
$3.19+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.12Pre-market26.10.12 17:18
●●●●●●●● ●●●●● ●●●●●●
New analyses demonstrate that MannKind’s Furoscix ReadyFlow autoinjector provides diuretic responses comparable to IV furosemide. These findings support the clinical utility of the device for managing edema in heart failure and chronic kidney disease patients in outpatient settings.…more
$3.19+0.00%vs prev closeShareBenzinga - 10.10Closed26.10.10 09:00
●●●●●●●● ●●●●● ●●●●●●
MannKind presented new clinical data at the HFSA 2026 meeting, demonstrating that Furoscix ReadyFlow offers IV-equivalent efficacy for heart failure and chronic kidney disease patients. As this data supports an already approved product, the market impact is expected to be neutral.…more
$3.19+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report